Rosemary Salvia rosmarinus Spenn.
Also called: Rosmarinus officinalis L. (synonym; name used in the EU monograph and 21 CFR 182.10), rosemary leaf
Rosemary (Salvia rosmarinus, long known as Rosmarinus officinalis) is a Mediterranean shrub whose leaves are used as a culinary herb, an herbal tea and a bath additive. Human trials are few and small.
- Category
- Botanical
- Part used
- Leaf (dried, whole or fragmented); rosemary oil used on the scalp in one trial
- Strongest evidence
- C Limited
- Native range
- Native to the Mediterranean (POWO: "Medit.")
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. No review stating a count was found. This entry cites 4 RCTs of rosemary alone: sources 2-5, oral leaf powder or capsules in three and topical rosemary oil (versus minoxidil) in one, 28 to 110 participants. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep2 topics
CSeveral areas, whole body or blood1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Memory speed in older adults (single doses) | C | A crossover trial in 28 older adults found 750 mg of dried leaf improved speed of memory versus placebo, while 6,000 mg impaired it; other measures showed less consistent harmful effects. [3] |
| Depression and anxiety (added to usual care) | C | An 8-week double-blind trial in major depressive disorder found rosemary capsules twice daily lowered depression and anxiety scores more than placebo. [2] |
| Androgenetic alopecia (pattern hair loss) | C | A 6-month randomized trial in 100 patients found similar hair-count gains with topical rosemary oil and 2% minoxidil; there was no placebo group. [4] |
| Fatty liver: liver enzymes, lipids and glucose | C | An 8-week double-blind RCT in 110 adults on a weight-loss diet found 4 g/day of rosemary leaf powder no better than placebo for liver enzymes, lipids or glucose. [5] |
Main constituents: Carnosic acid, carnosol, rosmarinic acid and the essential oil are the most studied constituents [1]; Rosmarinic acid measured at 21.13 ± 0.56 mg/g of dried plant in one trial's material [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied in trials: single doses of 750 mg to 6,000 mg of dried leaf powder in older adults. [3]
- Studied in trials: 4 g/day of rosemary leaf powder for 8 weeks in adults with fatty liver. [5]
- Stated in a regulatory monograph (EU, EMA HMPC, 2024), traditional use for dyspepsia: 1–2 g of leaf as tea, 2–3 times daily (2–6 g/day), from age 12. [6]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph (2024): safety during pregnancy and lactation has not been established; use is not recommended. No fertility data.
1 statement in the profile.
Details and sources - Interactions with medicinesNone reported
Medicines in general: EU monograph (EMA HMPC, 2024), section 4.5: none reported.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs2 statements
EU (EMA HMPC monograph, 29 May 2024), traditional use, adolescents and adults: dyspepsia and mild gut spasms — 1–2 g leaf in 150–250 ml boiling …
Details and sources
- Hypersensitivity (contact dermatitis) is listed as an undesirable effect, frequency not known (EU monograph). [6]
- The EU monograph lists bile-duct obstruction, cholangitis, liver disease, gallstones and other biliary disorders needing medical supervision as precautions for oral use. [6]
- Safety during pregnancy and lactation has not been established; the EU monograph does not recommend use then or in children under 12. [6]
- In the older-adult trial, the highest single dose (6,000 mg) impaired speed of memory. [3]
Identity, quality and standardization
- The EU monograph refers to leaf complying with the Ph. Eur. monograph (ref. 01/2013:1560). [6]
Regulatory status
- US: FDA's published NDI notification list has 3 entries naming rosemary (earliest NDI 908 submitted 2016-01-19; most recent NDI 1400 submitted 2025-04-30). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [7]
- EU: EMA's HMPC monograph (2024) recognizes traditional use of rosemary leaf orally for dyspepsia and mild gut spasms, and as a bath additive for minor muscular and joint pain and minor circulatory disorders. [6]
- US food use: 21 CFR 182.10 lists rosemary (Rosmarinus officinalis L.) among spices and natural seasonings generally recognized as safe for their intended use. [8]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming rosemary (earliest NDI 908 submitted 2016-01-19; most recent NDI 1400 submitted 2025-04-30). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
- Food use: 21 CFR 182.10 (spices and other natural seasonings and flavorings) lists rosemary (Rosmarinus officinalis L.) as generally recognized as safe for its intended use. [P3]
- Food use: 21 CFR 182.20 (essential oils, oleoresins and natural extractives) lists rosemary (Rosmarinus officinalis L.) as generally recognized as safe for its intended use. [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of rosemary was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P5]
- NTP technical reports list checked: no report on rosemary. [P6]
- EU monograph: tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. [P7]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Medicines in general: EU monograph (EMA HMPC, 2024), section 4.5: none reported. [P7]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of each dietary-ingredient lot (at least one appropriate test or examination) — Required for any component that is a dietary ingredient under 21 CFR 111.75(a)(1)(i), unless FDA grants a petition exemption. [P8]
- Compliance with the Ph. Eur. monograph for rosemary leaf (ref. 01/2013:1560) — The EU herbal monograph defines the herbal substance by this Ph. Eur. monograph. [P7]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (EMA HMPC monograph, 29 May 2024), traditional use, adolescents and adults: dyspepsia and mild gut spasms — 1–2 g leaf in 150–250 ml boiling water, 2–3 times daily (2–6 g/day); see a doctor if symptoms last over 2 weeks. [P7]
- EU (same monograph), bath additive for minor muscle and joint pain: 50 g as a decoction or directly in the bath, 2–3 times a week (35–38 °C, 10–20 minutes). [P7]
Pregnancy and breastfeeding
- EU monograph (2024): safety during pregnancy and lactation has not been established; use is not recommended. No fertility data. [P7]
Sources for this profile
- Andrade JM, et al. Rosmarinus officinalis L.: an update review of its phytochemistry and biological activity. Future Sci OA 2018;4(4):FSO283 (PMID 29682318), 2018-04. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 182.10 Spices and other natural seasonings and flavorings (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
- eCFR. 21 CFR 182.20 Essential oils, oleoresins (solvent-free), and natural extractives (including distillates) (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
- IARC Monographs. Agents Classified by the IARC Monographs, Volumes 1–142 (list last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list of 2-year studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency (HMPC). European Union herbal monograph on Rosmarinus officinalis L., folium. EMA/HMPC/513940/2021, Revision 1 (29 May 2024), 2024-05-29. ema.europa.eu
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
Sources
- Andrade JM, et al. Rosmarinus officinalis L.: an update review of its phytochemistry and biological activity. Future Sci OA 2018;4(4):FSO283 (PMID 29682318), 2018-04. pubmed.ncbi.nlm.nih.gov
- Azizi S, et al. Rosemary as an adjunctive treatment in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Complement Ther Clin Pract 2022;49:101685 (PMID 36343423), 2022-11. pubmed.ncbi.nlm.nih.gov
- Pengelly A, et al. Short-term study on the effects of rosemary on cognitive function in an elderly population. J Med Food 2012;15(1):10-7 (PMID 21877951), 2012-01. pubmed.ncbi.nlm.nih.gov
- Panahi Y, et al. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed 2015;13(1):15-21 (PMID 25842469), 2015-01. pubmed.ncbi.nlm.nih.gov
- Akbari S, et al. Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: a randomized, double-blind clinical trial. Phytother Res 2022;36(5):2186-2196 (PMID 35318738), 2022-05. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency (HMPC). European Union herbal monograph on Rosmarinus officinalis L., folium. EMA/HMPC/513940/2021, Revision 1 (29 May 2024), 2024-05-29. ema.europa.eu
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 182.10 Spices and other natural seasonings and flavorings (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Salvia rosmarinus Spenn. (accessed 2026-10-29). powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.